S
Salomon M. Stemmer
Researcher at Rabin Medical Center
Publications - 215
Citations - 12740
Salomon M. Stemmer is an academic researcher from Rabin Medical Center. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 43, co-authored 189 publications receiving 9651 citations. Previous affiliations of Salomon M. Stemmer include University of New South Wales & Tel Aviv University.
Papers
More filters
Journal ArticleDOI
Interventions for alleviating cancer-related dyspnea: A systematic review and meta-analysis
TL;DR: A systematic review and meta-analysis of randomized controlled trials demonstrating a beneficial effect to opioids in alleviating cancer-related dyspnea, and no advantage for the use of oxygen is demonstrated.
Journal ArticleDOI
A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non-Small Cell Lung Cancer.
Daniel A. Goldstein,Daniel A. Goldstein,Noa Gordon,Noa Gordon,Michal Davidescu,Moshe Leshno,Conor E. Steuer,Nikita Patel,Salomon M. Stemmer,Salomon M. Stemmer,Alona Zer,Alona Zer +11 more
TL;DR: Personalized dosing of pembrolizumab may have the potential to save approximately $0.825 billion annually in the United States, likely without impacting outcomes, and should be considered for the firstline management of PD-L1-positive advanced lung cancer.
Journal ArticleDOI
LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial.
Talia Golan,Ravit Geva,Ravit Geva,Donald A. Richards,Srinivasan Madhusudan,Boris Lin,Haofei Tiffany Wang,Richard A. Walgren,Salomon M. Stemmer +8 more
TL;DR: This work assessed LY2495655 (antimyostatin antibody) plus standard‐of‐care chemotherapy in pancreatic cancer using cachexia status as a stratifier and found no significant differences in the numbers of patients with and without cachexia.
Journal ArticleDOI
Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry.
Salomon M. Stemmer,Salomon M. Stemmer,Mariana Steiner,Shulamith Rizel,David B. Geffen,Bella Nisenbaum,Tamar Peretz,Lior Soussan-Gutman,Avital Bareket-Samish,Kevin Isaacs,Ora Rosengarten,Georgeta Fried,Debbie McCullough,Christer Svedman,Steven Shak,Nicky Liebermann,Noa Ben-Baruch +16 more
TL;DR: The findings support using endocrine therapy alone in ER+ HER2-negative breast cancer patients with micrometastases/1–3 positive nodes and Recurrence Score < 18 and suggest that only women with OncotypeDX scores under 18 can forgo chemotherapy.
Journal ArticleDOI
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).
Thomas Bachelot,Eva Ciruelos,Andreas Schneeweiss,Fabio Puglisi,T. Peretz-Yablonski,Igor Bondarenko,Shani Paluch-Shimon,Andrew M Wardley,J.-L. Merot,Y. du Toit,V. Easton,N. Lindegger,David Miles,K. Bouzid,Mario Campone,Bruno Coudert,Zbigniew Nowecki,Hassan Errihani,Florence Dalenc,Ana Ferreira,Max S. Mano,Francesco Ricci,Haralabos P. Kalofonos,Claudia Andreetta,Filippo Montemurro,Sophie Barrett,Qingyuan Zhang,Dimitris Mavroudis,Juan Matus,Carlos Beato,Xichun Hu,Rabab Gaafar,Hamdy Abdel Azeem,Christophe Perrin,Johannes Ettl,István Láng,Sunil Verma,Huiping Li,Etienne Brain,Oliver Hoffmann,Anna Cariello,Carlo Tondini,Taher Altwegeiri,Niklas Loman,Michael Lux,Antonio Frassoldati,Zeba Aziz,Fernando Salas,Joanna Streb,Andrzej Wronski,Salomón Menjón Beltrán,Irfan Cicin,Peter Schmid,Robert W. Laing,Zhongsheng Tong,Katalin Boér,Balazs Juhasz,Luca Gianni,Giuseppe Curigliano,Alejandro Juarez,Snezana Susnjar,Erika Matos,Ruchan Uslu,Hans Wildiers,Marcelo Rocha Cruz,Hugues Bourgeois,Raquel von Schumann,Salomon M. Stemmer,Flavia Morales Vásquez,Adriana Dominguez,Marek Z. Wojtukiewicz,Jasna Trifunovic,JJ Illarramendi,Laura Garcia,Yann Izarzugaza Peron,Maria Jose Echarri,Natliia Voitko,Duncan Wheatley,Simon Waters,Richard De Boer,Guy Jerusalem,Veronique Cocquyt,Carlos H. Barrios,Lawrence Panasci,Johanna Mattson,Minna Tanner,Michel Gozy,Georgios Vasilopoulos,János Révész,Luciano Latini,Cesare Gridelli,Jesus Lazaro,Antonio Gonzalez,Agusti Barnadas Molins,Eduardo Martinez,Jesús Alarcón,Ana Arance,Leif Klint,Oleksiy Kovalyov,Richard D. Baird,Belinda Yeo,Nicole McCarthy,Richard Greil,Shusen Wang,X. Artignan,Paule Augereau,Ingolf Juhasz-Boess,Roger K.C. Ngan,Hadassah Goldberg,Francesco Di Costanzo,Francesco Ferraù,Eduardas Aleknavicius,Kamran Rashid,Luís Costa,Jose Angel Garcia,Luis Ruiz de la Cruz,Rafael López,Olga Del Val,Ozgur Ozyilkan,Fathi Azribi,Mark Verrill,Nicholas C. Turner,Jane Beith,Andreas Petzer,Jurandyr Moreira de Andrade,Vanessa Bernstein,Daniel Rayson,Ibtessam Saad Eldin,Mihaëla Achille,Volkmar Mueller,Alessandra Gennari,Stefano Cascinu,Marwan Ghosn,Nagi S. El-Saghir,Joan Van den Bosch,Rianne Oosterkamp,Monika Kukulska,Ignacio Pelaez,Carolina Hernandez,Maria del Mar Gordon,Elsa Dalmau,Jose Luis Alonso,Sercan Aksoy,Hasan Şenol Coşkun,Yaroslav Shparyk,Mohini Varughese,Udaiveer Panwar,Lisa H Barraclough,Nicola Levitt,Jonathan Hicks,Anna Rigg,Mark Allen,Cecila Castillo,Luis Enrique Fein,Robin Stuart-Harris,Christian F. Singer,Herbert Stoeger,Sasha Smiljanic,Jifeng Feng,Miguel Cedeño,Jean-François Berdah,H. Orfeuvre,Anthony Goncalves,Eva-Maria Grischke,Eike Simon,Steffen Wagner,Anna Efremidou,Konstantinos Papazisis,Ella Evron,Moshe Inbar,Noa Ben Baruch,David B. Geffen,Natalya Karminsky,Enzo Maria Ruggeri,Cavanna Luigi,Donatella Grasso,Elona Juozaityte,Jeronimo Rafael Rodriguez Cid,Henk Roerdink,Neelum Siddiqi,José Luís Passos Coelho,Elisa Garcia Garre,Andres Garcia,Noelia Martinez Jañez,Maria Helena Lopez Ceballos,M Melé,Maria J. Garcia,Alberto Arcediano,Karen McAdam,Timothy J. Perren,Wendy Taylor,A. Humphreys,Raul Vera,Luis Alberto Kaen,Günther G. Steger,Johannes Andel,Jacques De Greve,Manon Huizing,Roberto Hegg,Anil A. Joy,Sandeep Sehdev,Riina Kütner,Johanna Ruohola,Nadine Dohollou,Jessica Grosjean,Philippe Laplaige,Rémy Largillier,Philippe Martin,Virginie Pottier,Jérôme Alexandre,Bernd Christensen,Dirk-Michael Zahm,Fariba Khandan,Hans-Joachim Lueck,Georgios Fountzilas,Georgeta Fried,Alice Giacobino,Andrea Bonetti,Yanin Chavarri Guerra,Laurens Van Warmerdam,Annette van der Velden,Suzan Vrijaldenhoven,Felix E de Jongh,Milagros Cavero,Raquel Andres Conejero,Adolfo Murias,Salvador Saura,Amparo Oltra,Andrés Redondo,Nuria Ribelles,Kilian Bachmeier,Johnathan Joffe,Prabir Chakraborti,Mark Beresford,Mohammad Butt,Christopher J. Poole,Gassan Yordi,Natasha Woodward,Gilberto Amorim,Nadia Califaretti,Susan Fox,Andre Robidoux,NanLi Li,Nenxiao Li,Jun Jiang,Tannia Soria,Peeter Padrik,Outi Saarni,Dominique Genet,Stéphanie Catala,Hugues Barletta,Luis Augusto Teixeira,Thomas Facchini,Tobias Hesse,Thorsten Kühn,Angelika Ober,Roland Repp,W. Schroeder,Dimitrios Pectasides,György Bodoky,Zsuzsanna Kahán,Irina Jiveliouk,Ora Rosengarten,Oscar Alabiso,Mario Perez,Yes Van de Wouw,Jolanta Smok-Kalwat,Margarida Damasceno,Gabriela Sousa,Omalkhair Abulkhair,A. Torres,Maria Purificación Martinez,Jesús Garcia Mata,Marta Santisteban Jesús Florián Jerico,Antonio Llombart,Rosa María Delgado Sánchez,Juan Carlos Torrego,Clara Olier Garate,César A. Rodríguez,Rosa Llorente,Diego Soto de Prado,Javier Cortes,Cristina Llorca,Antonio Galán,Gemma Viñas Villaro,Ulrik Narbe,Helena Granstam Bjömeklett,Sarah Westwell,Jackie Newby,Mariam Jafri,Robinson Rodriguez,Isabel Alonso +291 more
TL;DR: Paclitaxel appears to be a valid alternative taxane backbone to docetaxel, offering similar PFS and ORR with a predictable safety profile and preliminary findings from PERUSE suggest that the safety and efficacy of first-line pertuzumab, trastuzumAB and taxane for HER2-positive LR/MBC are consistent with results from CLEOPATRA.